Abstract
Background
Mucormycosis, a fungal infection caused by Rhizopus species is on the rise in COVID-19 patients as a result of their suppressed immunity. The current therapies include systemic administration of Amphotericin B.
Hypothesis and method
We screened several triazole broad-spectrum antifungal agents against the therapeutic target in mucormycosis using computational techniques like molecular docking and compared them with isavuconazole, an approved drug.
Result
The study concluded that 4 triazole drugs, pramiconazole, itraconazole, posaconazole and ketoconazole were strong candidates to be further evaluated and developed as a treatment for mucormycosis.
Conclusion
Novel topical and oral therapies could be developed from these drug leads.
【저자키워드】 Drug repurposing, molecular docking, Mucormycosis, Antifungal, Triazoles, 【초록키워드】 Treatment, therapy, Immunity, drugs, novel, administration, COVID-19 patient, Fungal infection, therapeutic target, amphotericin B, candidate, current therapy, Result, caused, include, evaluated, approved, screened, suppressed, Rhizopus, 【제목키워드】 molecular,